We report 6 cases of adverse systemic reactions to the intravesical instillation of doxorubicin hydrochloride for the treatment of recurrent superficial transitional cell carcinoma of the bladder. Although local reactions to this drug are common they rarely are life-threatening. Significant systemic toxicity has not been reported.